Alexandros Briasoulis1,2, Amgad Mentias3,4, Alexander Mazur3,4, Paulino Alvarez3,4, Enrique C Leira5, Mary S Vaughan Sarrazin6,7. 1. Division of Cardiovascular Diseases, Department of Internal Medicine, University of Iowa College of Medicine, 200 Hawkins Drive, Iowa City, IA, 52242, USA. alexbriasoulis@gmail.com. 2. National Kapodistrian University of Athens, Medical School, Athens, Greece. alexbriasoulis@gmail.com. 3. Division of Cardiovascular Diseases, Department of Internal Medicine, University of Iowa College of Medicine, 200 Hawkins Drive, Iowa City, IA, 52242, USA. 4. National Kapodistrian University of Athens, Medical School, Athens, Greece. 5. Departments of Neurology and Neurosurgery, Carver College of Medicine, and Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, USA. 6. Division of General Medicine, Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, IA, USA. 7. Comprehensive Access and Delivery Research and Evaluation Center, Iowa City VA Medical Center, Iowa City, IA, USA.
Abstract
BACKGROUND: Unlike warfarin direct oral anticoagulants (DOACs) are administered in fixed doses, which raises concerns of its effectiveness on larger patients. Data from randomized trials are limited on the safety and efficacy of DOACs in morbidly obese individuals with atrial fibrillation (AF). METHODS: We analyzed a cohort of obese (≥ 120 kg) and morbidly obese (BMI > 40 kg/m2) patients from the Veterans Health Administration system with AF who initiated apixaban, rivaroxaban, dabigatran, or warfarin between years 2012 and 2018. We used inverse probability of treatment weighting (IPTW) and Cox proportional hazards regression models to evaluate the relative hazard of death, myocardial infarction (MI), ischemic stroke, heart failure (HF), and bleeding events between oral anticoagulant (OAC) groups while censoring for medication cessation. RESULTS: We identified 6052 obese patients on apixaban, 4233 on dabigatran, 4309 on rivaroxaban, and 13,417 on warfarin (mean age 66.7 years, 91% males, 80.4% whites). At baseline patients on apixaban had the lowest glomerular filtration rate and highest rates of previous stroke and MI compared to other OACs. Among patients with weight ≥ 120 kg and those with BMI > 40 kg/m2, all DOACs were associated with lower risk of any hemorrhage, hemorrhagic stroke, and gastrointestinal (GI) bleeding. Patients with BMI > 40 kg/m2 treated with DOACs had similar ischemic stroke risk with those on warfarin. CONCLUSIONS: In this large cohort of obese Veterans Health Administration system patients, the use of DOACs resulted in lower hemorrhagic complications than warfarin while maintaining efficacy on ischemic stroke prevention.
BACKGROUND: Unlike warfarin direct oral anticoagulants (DOACs) are administered in fixed doses, which raises concerns of its effectiveness on larger patients. Data from randomized trials are limited on the safety and efficacy of DOACs in morbidly obese individuals with atrial fibrillation (AF). METHODS: We analyzed a cohort of obese (≥ 120 kg) and morbidly obese (BMI > 40 kg/m2) patients from the Veterans Health Administration system with AF who initiated apixaban, rivaroxaban, dabigatran, or warfarin between years 2012 and 2018. We used inverse probability of treatment weighting (IPTW) and Cox proportional hazards regression models to evaluate the relative hazard of death, myocardial infarction (MI), ischemic stroke, heart failure (HF), and bleeding events between oral anticoagulant (OAC) groups while censoring for medication cessation. RESULTS: We identified 6052 obese patients on apixaban, 4233 on dabigatran, 4309 on rivaroxaban, and 13,417 on warfarin (mean age 66.7 years, 91% males, 80.4% whites). At baseline patients on apixaban had the lowest glomerular filtration rate and highest rates of previous stroke and MI compared to other OACs. Among patients with weight ≥ 120 kg and those with BMI > 40 kg/m2, all DOACs were associated with lower risk of any hemorrhage, hemorrhagic stroke, and gastrointestinal (GI) bleeding. Patients with BMI > 40 kg/m2 treated with DOACs had similar ischemic stroke risk with those on warfarin. CONCLUSIONS: In this large cohort of obese Veterans Health Administration system patients, the use of DOACs resulted in lower hemorrhagic complications than warfarin while maintaining efficacy on ischemic stroke prevention.
Entities:
Keywords:
Atrial fibrillation; Bleeding; Direct oral anticoagulants; Obesity; Stroke
Authors: Manesh R Patel; Kenneth W Mahaffey; Jyotsna Garg; Guohua Pan; Daniel E Singer; Werner Hacke; Günter Breithardt; Jonathan L Halperin; Graeme J Hankey; Jonathan P Piccini; Richard C Becker; Christopher C Nessel; John F Paolini; Scott D Berkowitz; Keith A A Fox; Robert M Califf Journal: N Engl J Med Date: 2011-08-10 Impact factor: 91.245
Authors: Tingting Feng; Malmo Vegard; Linn B Strand; Lars E Laugsand; Bjørn Mørkedal; Dagfinn Aune; Lars Vatten; Hanne Ellekjær; Jan P Loennechen; Kenneth Mukamal; Imre Janszky Journal: Eur Heart J Date: 2019-09-07 Impact factor: 29.983
Authors: Rajiv Mahajan; Dennis H Lau; Anthony G Brooks; Nicholas J Shipp; Jim Manavis; John P M Wood; John W Finnie; Chrishan S Samuel; Simon G Royce; Darragh J Twomey; Shivshanker Thanigaimani; Jonathan M Kalman; Prashanthan Sanders Journal: J Am Coll Cardiol Date: 2015-07-07 Impact factor: 24.094
Authors: Nirmala Raghavan; Charles E Frost; Zhigang Yu; Kan He; Haiying Zhang; W Griffith Humphreys; Donald Pinto; Shiangyuan Chen; Samuel Bonacorsi; Pancras C Wong; Donglu Zhang Journal: Drug Metab Dispos Date: 2008-10-02 Impact factor: 3.922
Authors: Rachel M Kaplan; Celso L Diaz; Theresa Strzelczyk; Cindy You; Basil Saour; Michelle Fine; Amar Trivedi; Mark J Shen; Prasongchai Sattayaprasert; Alexandru B Chicos; Rishi Arora; Susan Kim; Albert Lin; Nishant Verma; Bradley P Knight; Rod S Passman Journal: Am J Cardiol Date: 2018-07-04 Impact factor: 3.133
Authors: Michael J Jamieson; Wonkyung Byon; Richard W Dettloff; Matthew Crawford; Peter S Gargalovic; Samira J Merali; Joelle Onorato; Andres J Quintero; Cristina Russ Journal: Am J Cardiovasc Drugs Date: 2022-05-16 Impact factor: 3.571
Authors: Joris J Komen; Tomas Forslund; Aukje K Mantel-Teeuwisse; Olaf H Klungel; Mia von Euler; Frieder Braunschweig; Håkan Wallén; Paul Hjemdahl Journal: Eur Heart J Cardiovasc Pharmacother Date: 2021-05-23